{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-11-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "letter_date": "02/07/2026",
      "approver_title": null,
      "file_name": "CRL_BLA125840_20260207.pdf",
      "letter_year": "2026",
      "approval_status": "Unapproved",
      "approver_name": null,
      "approver_center": [],
      "company_rep": "Steve Pakola, MD",
      "company_address": "9804 Medical Center Drive\nRockville, MD 20850",
      "company_name": "REGENXBIO, Inc.",
      "text": "g YN U.S. FOOD & DRUG\n\nADMINISTRATION\n\nOur STN: BL 125840/0 COMPLETE RESPONSE\nFebruary 7, 2026\n\nREGENXBIO, Inc.\n\nAttention: Steve Pakola, MD\n9804 Medical Center Drive\nRockville, MD 20850\n\nDear Dr. Pakola:\n\nPlease refer to your Biologics License Application (1b) (4) , for\nclemidsogene lanparvovee, (1)\n\nWe have completed our review of all the submissions you have made relating to this\nBLA. After our complete review, we have concluded that we cannot grant final approval\nbecause of the deficiencies outlined below.\n\nYou submitted a BLA for clemidsogene lanparvovec, a gene therapy for the requested\nindication of treatment of patients with mucopolysaccharidosis type II (MPS II, Hunter\nsyndrome). Your requested broad indication implies both neuronopathic and attenuated\n(non-neuronopathic) types of MPS II.\n\nMPS Il is a rare disorder of metabolism caused by mutations in the iduronate-2-\nsulfatase (IDS) gene. Deficiency of lysosomal enzyme results in progressive\naccumulation of glycosaminoglycans (GAGs) heparan sulfate (HS) and dermatan\nsulfate (DS) throughout body tissues and organs, leading to multi-organ dysfunction.\nThe neuronopathic form of disease is distinguished from the attenuated form by\npresence of neurological impairment.\n\nTo support this BLA under the accelerated approval pathway, you submitted the results\nfrom a single study, RGX-121-101, an open-label, multi-part study; Part 1 focused on\ndose-finding and safety, and Part 2 served as the pivotal single-arm study which\nevaluated clemidsogene lanparvovec administered as a single intracerebroventricular\n(ICV) or intracisternal (IC) dose in 13 pediatric patients aged 4 to 56 months with\nprotocol- defined neuronopathic MPS II. The Part 2 primary endpoint was the proportion\nof responders on a novel biomarker endpoint assessed in cerebrospinal fluid (CSF) at\nWeek 16, compared to the patient’s own baseline and informed by an external natural\nhistory control.\n\nAlthough we agreed in principle to the study protocol, we expressed concerns\nthroughout your development program at the Pre-IND, IND, and BLA meetings (b) (4)\n\nU.S. Food & Drug Administration\n10903 New Hampshire Avenue\nSilver Spring, MD 20993\nwww.fda.gov\n\nPage 2 — STN BL 125840 — Steve Pakola, MD\n\n(b) (4). Specifically, FDA expressed concerns regarding the uncertainty of the study\neligibility criteria to adequately define a population with neuronopathic disease,\ncomparability of the natural history external control to the study population, and the\nappropriateness of CSF HS D2S6 with the proposed performance threshold as a\nreasonably likely surrogate endpoint to predict clinical benefit on cognitive outcomes in\nsupport of a marketing application. FDA indicated that you could pursue an accelerated\napproval pathway, but the aforementioned concerns should be adequately addressed to\nprovide substantial evidence of effectiveness and may be review issues at the time of\nBLA submission.\n\nWe continued to exercise applicable regulatory flexibilities by evaluating the totality of\nthe data from one single arm study with a small sample size compared to limited\nexternal control data and utilizing a novel biomarker. The biomarker CSF HS D2S6 has\nnot been used for any previous regulatory decision and is not routinely assessed as part\nof standard clinical practice. It lacks support from published literature as a biomarker for\nthis disease and has no established performance threshold to differentiate\nneuronopathic from attenuated forms of MPS II, or to detect treatment response.\n\nDuring our multidisciplinary review of your BLA, including consultation with FDA cross-\ncenter subject matter experts, we noted that the small, enrolled population of 13\npatients had uncertain phenotype of the neuronopathic disease, an inadequate control,\nand insufficient support for a performance threshold for the novel CSF HS D2S6\nbiomarker. In addition, we considered the procedural and emergent safety risks of your\ngene therapy.\n\nDespite exercising regulatory flexibility, given the breadth of uncertainties, we are\nunable to conclude that the RGX-121-101 study is an adequate and well-controlled\nstudy. As communicated during the Late Cycle Meeting (1b) (4) ), the data\nfrom the RGX-121-101 Part 2 study are insufficient to provide substantial evidence of\neffectiveness to support approval of clemidsogene lanparvovec for the proposed\nindication of treatment of patients with MPS II, or for the narrower indication of\nneuronopathic MPS II pursued during clinical development.\n\nThe specific deficiencies are explained in detail as follows:\n1. Identification of a target population with neuronopathic MPS II\n\nExpert consensus is lacking to differentiate neuronopathic from attenuated disease\nin younger MPS II patients who have not yet reached the age at which cognitive\nplateau or decline is expected for the neuronopathic form. Patients were only\nrequired to meet one and not all four eligibility criteria (two based on /DS mutations\nand/or two based on neurodevelopmental scale scores) to define neuronopathic\nMPS II disease, leading to further heterogeneity and raising uncertainty that the\nenrolled population is representative of the target population.\n\n\nPage 3 — STN BL 125840 — Steve Pakola, MD\n\nOf the Part 2 pivotal study patients, 62% (8/13) were classified as having\nneuronopathic disease based on their specific DS gene mutation, and 46% (6/13)\nbased on a baseline Bayley Scales of Infant Development, 3rd Edition (BSID-III)\ncognitive score one standard deviation or more below the normative mean. One\npatient was classified by both.\n\nThe specific challenges with identification of a target population with neuronopathic\nMPS II are as follows:\n\na. Defining neuronopathic disease based on a specific genetic mutation is\nproblematic because some mutations in the /DS gene contribute to a\nheterogenous disease presentation with a spectrum of severity inclusive of\npatients with and without cognitive impairment or have only been reported ina\nvery small number of patients. Therefore, the genotype-phenotype correlation is\nnot well-characterized.\n\nAmong the 8 patients defined as having neuronopathic disease based on a\nspecific /DS mutation, mutations generally associated with neuronopathic\ndisease (e.g., large/whole gene deletions, inversions) were present in only 5\npatients (63%), whereas the remaining 3 patients (38%) had a mutation with an\nunclear phenotypic correlation.\n\nb. It is unclear if BSID-III cognitive scores one standard deviation (SD) or more\nbelow the normative mean identify cognitive impairment in study patients\nsufficiently to adjudicate their disease type (attenuated or neuronopathic) for\nstudy eligibility. This criterion encompasses a broad range of impairment, from at\nrisk for developmental delay to severe cognitive impairment. Patients with\nattenuated disease may experience mild impairment, and there is no consensus\non a threshold level of cognitive impairment that distinguishes attenuated from\nneuronopathic disease phenotypes. Additionally, limitations in performance-\nbased testing in younger patients and those with hearing impairment challenge\nthe interpretation of BSID-III results to accurately assess cognition for the\npurposes of phenotype determination.\n\nAmong the 6 patients defined as having neuronopathic disease based on BSID-\nIll cognitive scores (one SD or more below the normative mean), FDA\nconfirmation of phenotype is challenging in very young patients less than one\nyear of age (1/6, 17%), patients with mild cognitive impairment (3/6, 50%), and/or\nwith concurrent hearing impairment (5/6, 85%).\n\n2. Choice of control\n\na. Lack of comparability between trial patients and external control population used\nto define the primary endpoint\n\nPage 4 — STN BL 125840 — Steve Pakola, MD\n\nThe proposed threshold for CSF HS D2S6 is further compromised by lack of\ncomparability between the Part 2 patients and the external control MPS II\npatients due to differences in patients’ key characteristics such as age and\nvarying definitions of cognitive impairment to distinguish attenuated from\nneuronopathic MPS II.\n\nUsing patients as their own control\nDuring our review, we noted intra-patient variability in CSF HS D2S6 levels.\n\nIn response to a question raised during the Late Cycle Meeting discussion\n\n(b) (4) , you later clarified that CSF was sampled by different\nroutes, such as lumbar puncture vs. ICV, during the pre-treatment period, but all\npost-treatment samples were via lumbar puncture. This may have contributed to\nintra-patient variability.\n\nWe noted that 2 patients in Part 2 had pre-treatment CSF HS D2S6 level less\nthan 100 ng/ml, which essentially made their data not evaluable to assess the\ntreatment effect with clemidsogene lanparvovec.\n\nThese factors further complicate the interpretation of the surrogate endpoint.\n\n3. Uncertainty that the primary endpoint of CSF HS D2S6 is reasonably likely to predict\nclinical benefit\n\nYou propose CSF HS D2S6 is a surrogate endpoint reasonably likely to predict\ncognitive outcomes. You defined “responders” as patients who at Week 16 achieved\nreduction in CSF HS D2S6 levels to at or below the upper limit detected in\nattenuated MPS II patients, which was subsequently clarified to mean less than 100\nng/ml and confirmed in the Statistical Analysis Plan dated (1) (4) . This\nCSF HS D2S6 biomarker threshold has been proposed for the purposes of this\napplication without external expert or scientific consensus. Specific deficiencies\nrelated to surrogate endpoint suitability are as follows:\n\na.\n\nInsufficient evidence for use of CSF HS D2S6 as a surrogate endpoint\nreasonably likely to predict clinical benefit\n\nIn your submission, you provided correlation analysis between CSF HS D2S6\nlevel and cognitive function based on BSID-III scores. There was no natural\nhistory data provided for BSID-III scores to be able to model the expected timing\nof plateau and decline in untreated disease, and the timing of expected cognitive\nchanges varies substantially in the published literature. Published analysis’ from\nyour natural history study (which evaluated neurodevelopment on a scale that\n\n1 Phillips, D., Cho, Y., Mulatya, C., Forsberg, M., Poe, M., & Escolar, M. (2024). Retrospective Natural History Study\nof neurodevelopment in neuronopathic Mucopolysaccharidosis Type Il. Medical Research Archives, 12(11).\ndoi:10.18103/mra.v12i1 1.5915\n\nPage 5 — STN BL 125840 — Steve Pakola, MD\n\ncannot be directly compared to BSID-III) suggests patients may acquire new\nskills until an inflection point (i.e., plateau period) which occurs between 66.1 to\n74.6 months of age. Study patients were not followed to a sufficient age to\nevaluate for a deviation from the natural history. Additionally, cognitive changes\nwere challenging to assess over a short duration of follow-up of only 52 weeks\nfor most Part 2 patients. Therefore, the available data is not sufficient to support\nthe correlation analysis between change in CSF HS D2S6 levels and cognitive\noutcomes.\n\n. Insufficient evidence to support the proposed threshold of CSF HS D2S6 and\nutility in differentiating disease phenotypes\n\nYou did not provide sufficient evidence supporting the proposed threshold of\nreduction of CSF HS D2S6 levels to less than 100 ng/ml and its ability to predict\na clinically meaningful benefit.\n\nThis threshold was derived from a study which analyzed CSF samples from 51\npatients; however, only 14% (7/51) were MPS II patients external to the RGX-\n121-101 study, including 6% (3/51) with neuronopathic disease and 8% (4/51)\nwith attenuated disease. The proposed threshold's accuracy to differentiate\nbetween the two disease phenotypes is unclear. This was due to the small\nnumber of external patients with MPS II, including only 4 with attenuated disease\nto define the threshold, and no external validation of the threshold was provided.\n\nThe threshold is further challenged by at least one pre-treatment CSF HS D2S6\nlevel less than 100 ng/ml in 5 patients across all the clemidsogene lanparvovec\n\ninterventional studies, including 2 patients characterized as having profound\n\ncognitive impairment at baseline.\n\nWe acknowledge the importance of early treatment and the need for therapies for\n\npatients with neuronopathic MPS II. We recognize the difficulties in\n\nproviding robust\n\nefficacy data from the RGX-121-101 study, given that neuronopathic disease cannot be\nreliably identified during the presymptomatic stage, and the proposed biomarker of CSF\n\nHS D2S6 lacks sufficient evidence to support the proposed thresho!\ndisease phenotypes and predict clinical outcomes.\n\nid to differentiate\n\nPotential paths forward would be to demonstrate normalization of or a meaningful\n\nchange in a relevant biomarker, or neurodevelopmental outcomes tl\n\nhat deviate from the\n\nnatural history of disease. You may choose to perform a new clinical study or enroll\nadditional patients in your RGX-121-101 study and continue to follow patients with\nneuronopathic MPS II treated in study RGX-121-101, using stored CSF samples for\nbiomarker analysis and longer neurodevelopmental follow-up. We recommend that you\n\nuse an appropriate untreated control comparable to the study popul\n\nlation on key factors\n\nsuch as age, stage of disease, and neurodevelopmental assessments, and an\n\nadjudication committee comprised of subject matter experts that sel\n\nlects the targeted\n\nPage 6 — STN BL 125840 — Steve Pakola, MD\n\npopulation based on multiple pre-defined factors to improve the interpretability of the\nstudy results.\n\nWe look forward to collaboratively working with you on a study design that adequately\nminimizes confounding from the above-mentioned factors.\n\nWe reserve comments on the proposed labeling until the application is otherwise\nacceptable. We may have comments when we see the proposed draft final labeling.\n\nADDITIONAL COMMENTS\nIn addition, we have the following comments that do not preclude approval.\n\n4. In your future resubmission, consider addressing the following potential confounders\nto improve interpretability of study results:\n\na. Concomitant treatments\n\nYou did not provide sufficient evidence characterizing the potential effect of\nenzyme replacement therapy (ERT) on biomarkers and clinical outcomes in a\nyounger population such as that of the Part 2 study. ERT was variably used\namongst the Part 2 study patients, in that some patients were ERT-naive (5/13),\nsome continued ERT through the duration of follow-up (2/13), one patient started\nERT during the study, and six patients discontinued ERT during the study\n(including 2 patients who later restarted). Given the uncertain effect of ERT on\nstudy outcomes and variable use of ERT amongst Part 2 study patients, study\nresults may have been confounded by concomitant ERT use.\n\nThe impact of immunosuppression on CSF HS D2S6 levels is uncertain since all\nstudy patients were still receiving immunosuppression at the time of the primary\nendpoint assessment. Additionally, we note that duration of follow up is\ninsufficient to establish stabilization of CSF HS D2S6 levels following\ndiscontinuation of immunosuppression.\n\nb. Patient factors\n\nIt is unclear if patient factors such as age and MPS II disease features and\nprogression status (e.g., pre-symptomatic versus early symptomatic, symptoms\nsuch as seizures, MRI volumetric brain loss) are associated with differences in\nCSF HS D2S6 and other biomarker levels.\n\n5. There was missing data for several key covariates such as hearing assessments\nand timing of ERT administration that challenged interpretability of study results. In\nyour future resubmission, please include a discussion on how missing data\npotentially impacts interpretability of study results and the steps you have taken to\nmitigate issues related to missing data within your statistical analyses.\n\nPage 7 — STN BL 125840 — Steve Pakola, MD\n\n6. Acase of a malignant brain tumor following treatment with a gene therapy product\n(RGX-111, under development for MPS |) with a similar viral vector, such as shared\ncapsid and vector genome design, was reported. Because AAV vector integration\nwas reported in the tumor tissue, potentially similar safety risks may exist for\nclemidsogene lanparvovec. This adverse event may lead to a requirement for a\nsafety PMR for BLA 125840 in the future. In your future resubmission, include an\nupdated safety summary and benefit-risk assessment incorporating your findings of\nvector integration analysis in MPS programs.\n\nYour responses to our requests for additional information may be addressed in a\nseparate amendment to the BLA.\n\nWithin one year after the date of this letter, you are required to resubmit or withdraw the\napplication (21 CFR 601.3(b)). If you do not take one of these actions, we may consider\nyour lack of response a request to withdraw the application under 21 CFR 601.3(c).\n\nYou may also request an extension of time in which to resubmit the application. A\nresubmission must fully address all the deficiencies listed. A partial response to this\nletter will not be processed as a resubmission and will not start a new review cycle.\n\nYou may request a Type A post-action meeting within 3 months of the date of this letter.\nPlease submit your meeting request as described in the guidance for industry Formal\nMeetings Between the FDA and Sponsors or Applicants of PDUFA Products at\nhttps://www.fda.gov/media/172311/download, and CBER’s SOPP 8101.1 Scheduling\nand Conduct of Regulatory Review Meetings with Sponsors and Applicants at\nhttp://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceReqgulatoryInformation\n/ProceduresSOPPs/ucm079448.htm.\n\nIf you have any questions regarding the above, please contact the (1b) (4)\n\nSincerely,\n\n(b) (4)\n\nCenter for Biologics Evaluation and Research\n",
      "application_number": [
        "BL 125840"
      ],
      "letter_type": "COMPLETE RESPONSE"
    }
  ]
}